


JI-101

Chemical Properties

CAS No. :	900573-88-8
Formula:	C ₂₂ H ₂₀ BrN ₅ O ₂
Molecular Weight:	466.33
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR- β), and ephrin type-B receptor 4 (EphB4).
Targets(IC50)	Ephrin Receptor, PDGFR, VEGFR

Solubility Information

Solubility	DMSO: 27.5 mg/mL (58.97 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.29 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1444 mL	10.722 mL	21.444 mL
5 mM	0.4289 mL	2.1444 mL	4.2888 mL
10 mM	0.2144 mL	1.0722 mL	2.1444 mL
50 mM	0.0429 mL	0.2144 mL	0.4289 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Mark L. Wade, Neeraj Agarwal et al. A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR- β , and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. *Investigational New Drugs*, December 2015, Volume 33, Issue 6, pp 1217-1224

S. D. Gurav, Jeniffer et al. Pharmacokinetics, Tissue Distribution and Identification of Putative Metabolites of JI-101 - A Novel Triple Kinase Inhibitor in Rats. *Arzneimittelforschung* 2012; 62(01): 27-34.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481